Trial Profile
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study in 60 Healthy Tubal-ligated Women Aged 18 to 45 Years Investigating the Pharmacodynamic Effects of 5 Different Doses (0.1 - 5 mg) BAY1002670 After Daily Oral Administration Over 84 Days
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Oct 2018
Price :
$35
*
At a glance
- Drugs Vilaprisan (Primary)
- Indications Uterine leiomyoma
- Focus Proof of concept; Therapeutic Use
- Sponsors Bayer
- 10 Oct 2018 Results of an exploratory analysis presented at the American Society for Reproductive Medicine Scientific Congress 2018
- 24 Mar 2015 Results of pharmacodynamic study will be presented at the Society for Reproductive Investigation (SRI) 62nd Annual Scientific Meeting, according to Bayer HealthCare media release.
- 30 Mar 2013 New trial record